The U.S. Food and Drug Administration (FDA) has granted approval to Moderna for its new lower-dose COVID-19 vaccine, named mNexspike. This next-generation vaccine is specifically authorized for adults aged 65 and older and those with certain health conditions, indicating a focused approach to vaccination in higher-risk populations. However, the approval comes with restrictions, limiting its use primarily to the specified age group and individuals with health conditions, thereby excluding most healthy young adults from eligibility.